ABUS vs MET · P/E 5.4, rev $6.2M vs P/E 13, $52.16B cap
Arbutus Biopharma Corp (ABUS) versus MetLife Inc (MET) — a side-by-side from cached financials, not a winner call.
Arbutus Biopharma Corp (ABUS) is a biotechnology company listed on NASDAQ.
MetLife Inc (MET) is a insurance - life company listed on US.
Latest reported ABUS revenue for 2024-12-31 was $6.2M. Net income was -$69.9M. Revenue was down 66.0% from 2023-12-31 to 2024-12-31. ABUS currently screens at market cap $883.0M and trailing P/E 5.4.
MET does not have a complete income-statement cache yet.
ABUS currently screens at market cap $883.0M and trailing P/E 5.4. MET currently screens at market cap $52.16B and trailing P/E 12.7.
Not investment advice. Open the ABUS and MET stock pages for the full models.
Not investment advice.